跳转至内容
Merck
CN
  • Haemodialysis in Diabetic Patients Modulates Inflammatory Cytokine Profile and T Cell Activation Status.

Haemodialysis in Diabetic Patients Modulates Inflammatory Cytokine Profile and T Cell Activation Status.

Scandinavian journal of immunology (2015-05-15)
A Almeida, O Lourenço, A M Fonseca
摘要

Diabetic nephropathy (DN) is a common complication in patients with diabetes, and most of them need renal replacement therapy such as haemodialysis (HD). These patients have a high tendency to develop infections and exhibit anomalies in the immune system. The objective of this study was to assess the expression of activation-related markers on T cells, as well as to quantify inflammatory cytokines, before and after a single HD session in DN patients. The study involved DN patients under HD treatment who signed an informed consent form. Blood samples before and after one HD session were collected, to analyse the expression of CD25, CD69 and CD71 in T cells. We also quantified IL-12p70, IL-8, IL-10, IL-1β, TNF-α and IL-6 in serum samples using the cytometric bead array technique. After the HD session, there was an increase in the CD4/CD8 ratio due to significant alterations in both subsets. The relative percentage of CD25+ cells and CD8+ CD25+ increased significantly after the HD session, while the relative percentage of CD69 T cells decreased. There was a significant decrease in the CD25 mean fluorescence intensity values for CD4+ T, as well as in the case of CD71 in T cells after the HD session. Regarding cytokine synthesis, we found a significant increase in IL-10 and IL-6 and a decrease in IL-8 after HD session. This study showed that a HD session in DN patients affects the T cell activation status in the two major subpopulations and differentially modulates the production of inflammatory cytokines.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, BioReagent, suitable for fluorescence, mixture of 2 components, ≥90% (HPLC)
Sigma-Aldrich
荧光素 5(6)-异硫氰酸酯, ≥90% (HPLC)
Sigma-Aldrich
荧光素异硫氰酸酯异构体I, ≥97.5% (HPLC)